Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
10%
Biological Product
8%
Calgranulin
6%
Clinical Trial
17%
Clinical Trial Design
7%
Cohort Study
5%
Combination Therapy
15%
Crohn's Disease
20%
Diseases
18%
Drug Development
6%
Inflammation
6%
Inflammatory Bowel Disease
100%
Infliximab
5%
Interleukin 23
6%
Janus Kinase Inhibitor
17%
Mercaptopurine
6%
Observational Study
6%
Randomized Controlled Trial
11%
Remission
24%
Tofacitinib
12%
Ulcerative Colitis
45%
Upadacitinib
5%
Ustekinumab
7%
Medicine and Dentistry
Acneiform Eruption
7%
Advanced Therapy
9%
Biological Marker
6%
Biological Product
8%
Clinical Trial
14%
Clinical Trial Design
11%
Clinician
5%
Cohort Effect
7%
Combination Therapy
12%
Crohn's Disease
17%
Diseases
16%
Health Care Cost
6%
Inflammatory Bowel Disease
97%
Janus Kinase Inhibitor
20%
Observational Study
5%
Personalized Medicine
7%
Placebo
5%
Quality of Life
5%
Retrospective Cohort Study
7%
Ulcerative Colitis
22%
Vedolizumab
7%